Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer.
Christopher T SuEmily NizialekJacob E BerchuckPanagiotis J VlachostergiosRyan AshkarAlexandra O SokolovaPedro C BarataRahul R AggarwalRana R McKayNeeraj AgarwalHeather M McClureNellie N NafissiAlan H BryceA Oliver SartorNicolas SayeghHeather H ChengNabil AdraCora N SternbergMary-Ellen TaplinMarcin CieslikAjjai S AlvaEmmanuel S AntonarakisPublished in: The Prostate (2022)
Our retrospective data suggest differential response between ATM and BRCA2 mutated prostate cancers in terms of response to PARPi and to taxane chemotherapy. When considering the sequence of PARPi versus taxane chemotherapy for mCRPC with DDR mutations, ATM, and BRCA2 mutation status may be helpful in guiding choice of initial therapy.